Skip to main content
Research
Research

Aplin Research

Contact

Andrew Aplin, PhD
  • Deputy Director, Sidney Kimmel Comprehensive Cancer Center
  • Kalbach-Newton Professor in Cancer Research
Department of Pharmacology, Physiology & Cancer Biology

233 S 10th Street
BLSB 1050
Philadelphia, PA 19107

Publications

Recent Publications

A Phase II Trial of Defactinib Combined with Avutometinib in Patients with Metastatic Uveal Melanoma

Meeting Report From the 2025 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Amsterdam, the Netherlands, October 2025

Erratum: Editor's Note: Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma (Cancer research (2019) 79 9 DOI: 10.1158/0008-5472.CAN-18-3177.)

Diacylglycerol Kinase Eta as a Novel Target in NRAS Mutant Melanoma

Pyroptosis Modulates Multiple Immune Cell Populations in Targeted Therapy–Treated Melanoma

S-phase targeted treatment triggers caspase-dependent lytic immunogenic cell death with pyroptotic features in cancers

SETDB1 is critically required for uveal melanoma growth and represents a promising therapeutic target

Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma models

Aqueous humor biomarkers in ocular oncology: Insights and advances

Inhibition of anti-apoptotic BCL2 overcomes adaptive resistance to co-targeting of the protein kinase FAK and MEK in GNAQ-driven uveal melanoma

Elevated Transglutaminase-2 in SOX10-Deficient Melanoma Promotes Tumor Onset and Decreases Intratumoral CD4+ T Cells

Correction: Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma (Cancer Res (2019) 79 (2415-25) DOI: 10.1158/0008-5472.CAN-18-3177)

Facts and Hopes: Toward the Next Quantum Leap in Melanoma

Metabolic Inhibition Induces Pyroptosis in Uveal Melanoma

FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma

Elevated NR2F1 underlies the persistence of invasive disease after treatment of BRAF-mutant melanoma

Meeting Report From the 2023 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Philadelphia, PA, November 2023

Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma

SOX10 Loss Sensitizes Melanoma Cells to Cytokine-Mediated Inflammatory Cell Death

Slow proliferation of BAP1-deficient uveal melanoma cells is associated with reduced S6 signaling and resistance to nutrient stress

Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma

High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma

Targeting TEAD-ious resistance

Gene signature reveals decreased SOX10-dependent transcripts in malignant cells from immune checkpoint inhibitor-resistant cutaneous melanomas

MacroH2A restricts inflammatory gene expression in melanoma cancer-associated fibroblasts by coordinating chromatin looping

Publications

Scopus Feed has no publications.

Go Back to Aplin Research